Strand Natalie H, Whitney Madeline, Johnson Brooks, Dunn Tyler, Attanti Sumedha, Maloney Jillian, Misra Lopa, Gomez Diego, Viswanath Omar, Emami Eric, Leathem James
Division of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.
Mayo Clinic Alix School of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.
Curr Pain Headache Rep. 2025 Jan 7;29(1):15. doi: 10.1007/s11916-024-01353-0.
Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.
These substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.
慢性疼痛影响着全球约15亿人，是导致残疾的主要原因，也是医疗系统的重大经济负担。传统治疗方法，如阿片类药物和非甾体抗炎药，常常与不良反应相关，包括成瘾和胃肠道问题，而且长期缓解效果往往有限。本综述探讨了致幻剂，包括裸盖菇素、麦角酸二乙酰胺（LSD）和氯胺酮，作为慢性疼痛管理中替代治疗药物的潜力。
这些物质通过作用于血清素能和谷氨酸能系统来调节疼痛感知，并可能促进神经可塑性，为缓解疼痛提供了新途径。具体而言，该综述详细阐述了致幻剂的药理作用、它们对癌症疼痛、偏头痛和神经性疼痛等慢性疼痛综合征的影响及其临床意义。研究考察了这些化合物的安全性、患者反应和镇痛特性，强调需要进一步研究以验证其疗效并优化其在疼痛管理中的治疗应用。
